Literature DB >> 29203995

Management of Borderline Ovarian Tumors-Still a Gray Zone.

Nidhi Nayyar1, Prerna Lakhwani1, Ashish Goel1, Pankaj Kr Pande1, Kapil Kumar1.   

Abstract

Borderline ovarian tumors (BOTs) are a heterogeneous group of non-invasive epithelial ovarian tumors that occur at a younger age, present in early stage, frequently associated with infertility but are easily curable. Although they may have symptomatic long-term recurrences, they have an excellent prognosis in spite of peritoneal spread. Among the epithelial tumors of the ovary, BOTs fall in the spectrum lying between cystadenomas (benign) and cystadenocarcinomas (malignant). Their oncological behavior is more aggressive than benign ovarian tumors but relatively less than that of malignant ovarian tumors. Since the age group affected is usually young females, preservation of fertility is an important aspect of treatment protocol. Although the management of these tumors has been extensively discussed, it still remains a controversial gray zone. In this review, epidemiology, pathogenesis, histologic subtypes, various surgical approaches, follow-up, and management of recurrence have been discussed. Choosing the best treatment still poses a challenge for the treating oncosurgeon.

Entities:  

Keywords:  Borderline ovarian tumors; Fertility-sparing surgery; Restaging surgery

Year:  2017        PMID: 29203995      PMCID: PMC5705520          DOI: 10.1007/s13193-017-0697-3

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  53 in total

1.  Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study.

Authors:  G Zanetta; S Rota; S Chiari; C Bonazzi; G Bratina; C Mangioni
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary.

Authors:  J Kaern; C Trope; K E Kjorstad; V Abeler; E O Pettersen
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

3.  Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.

Authors:  Nathalie L G Sieben; Jan Oosting; Adrienne M Flanagan; Jaime Prat; Guido M J M Roemen; Sandra M Kolkman-Uljee; Ronald van Eijk; Cees J Cornelisse; Gert Jan Fleuren; Manon van Engeland
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  Prognostic value of lymph node involvement in ovarian serous borderline tumors.

Authors:  Benedicte Lesieur; Aminata Kane; Pierre Duvillard; Sebastien Gouy; Patricia Pautier; Catherine Lhommé; Philippe Morice; Catherine Uzan
Journal:  Am J Obstet Gynecol       Date:  2011-02-24       Impact factor: 8.661

5.  Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

Authors:  F Trillsch; S Mahner; L Woelber; E Vettorazzi; A Reuss; N Ewald-Riegler; N de Gregorio; C Fotopoulou; B Schmalfeldt; A Burges; F Hilpert; T Fehm; W Meier; P Hillemanns; L Hanker; A Hasenburg; H G Strauss; M Hellriegel; P Wimberger; K Baumann; M D Keyver-Paik; U Canzler; K Wollschlaeger; D Forner; J Pfisterer; W Schroeder; K Muenstedt; B Richter; F Kommoss; S Hauptmann; A du Bois
Journal:  Ann Oncol       Date:  2014-03-11       Impact factor: 32.976

6.  Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.

Authors:  J D Seidman; R J Kurman
Journal:  Am J Surg Pathol       Date:  1996-11       Impact factor: 6.394

7.  Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential.

Authors:  B M Ronnett; R J Kurman; C M Zahn; B M Shmookler; K A Jablonski; M E Kass; P H Sugarbaker
Journal:  Hum Pathol       Date:  1995-05       Impact factor: 3.466

Review 8.  The behavior of serous tumors of low malignant potential: are they ever malignant?

Authors:  R J Kurman; C L Trimble
Journal:  Int J Gynecol Pathol       Date:  1993-04       Impact factor: 2.762

9.  Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.

Authors:  Raffaèle Fauvet; Joëlle Boccara; Charlotte Dufournet; Emmanuel David-Montefiore; Christophe Poncelet; Emile Daraï
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

10.  In vitro fertilization is associated with an increased risk of borderline ovarian tumours.

Authors:  Louise M Stewart; C D'Arcy J Holman; Judith C Finn; David B Preen; Roger Hart
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

View more
  2 in total

1.  Evaluation the Presence of SERPINA5 (Exon 3) and FTO rs9939609 Polymorphisms in Papillary Thyroid Cancer Patients.

Authors:  Seyed Mohammad Moshtaghioun; Nasim Fazel-Yazdi; Mohammad Mandegari; Ahmad Shirinzadeh-Dastgiri; Mohammad Vakili; Habib Fazel-Yazdi
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

2.  Uncommon borderline ovarian tumours: A clinicopathologic study of seventeen patients

Authors:  Dilek Yüksel; Caner Çakır; Günsu Kimyon Cömert; Çiğdem Kılıç; Yasin Durmuş; Nurettin Boran; Gökhan Boyraz; Alper Karalök; Taner Turan
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-09-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.